Dirlotapide

Dirlotapide
Clinical data
Trade namesSlentrol
AHFS/Drugs.comInternational Drug Names
Routes of
administration
By mouth
ATCvet code
Legal status
Legal status
Pharmacokinetic data
Protein bindingHigh[1]
MetabolismLiver
Elimination half-life5–18 hours (increased with repeated dosing)
ExcretionFeces, urine
Identifiers
  • 1-Methyl-N-[(1S)-2-(methyl-(phenylmethyl)amino)-2-oxo-1-phenylethyl]-5-[[oxo-[2-[4-(trifluoromethyl)phenyl]phenyl]methyl]amino]-2-indolecarboxamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC40H33F3N4O3
Molar mass674.724 g·mol−1
3D model (JSmol)
  • FC(F)(F)c1ccc(cc1)c2ccccc2C(=O)Nc3cc4c(cc3)n(c(c4)C(=O)N[C@@H](c5ccccc5)C(=O)N(Cc6ccccc6)C)C
  • InChI=1S/C40H33F3N4O3/c1-46(25-26-11-5-3-6-12-26)39(50)36(28-13-7-4-8-14-28)45-38(49)35-24-29-23-31(21-22-34(29)47(35)2)44-37(48)33-16-10-9-15-32(33)27-17-19-30(20-18-27)40(41,42)43/h3-24,36H,25H2,1-2H3,(H,44,48)(H,45,49)/t36-/m0/s1 checkY
  • Key:TUOSYWCFRFNJBS-BHVANESWSA-N checkY
  (verify)

Dirlotapide is a drug used to treat obesity in dogs.[1] It is manufactured by Pfizer and Zoetis and marketed under the brand name Slentrol.[citation needed]

It works as a gut-selective microsomal triglyceride transfer protein (MTTP or MTP) inhibitor.[2] This blocks the assembly and release of lipoproteins into the bloodstream, thereby reducing fat absorption.[medical citation needed] It also elicits a satiety signal from lipid-filled cells lining the intestine.[medical citation needed]

  1. ^ a b "Slentrol (dirlotapide) Oral Solution (5 mg/ml, 1%) for Use in Dogs Only. Full Prescribing Information" (PDF). zoetisUS.com. Pfizer Animal Health. Div. of Pfizer Inc. NY, NY 10017. Archived from the original (PDF) on 8 December 2015. Retrieved 28 November 2015.
  2. ^ US 20160002264, "Carbocyclic- and Heterocyclic-Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds", assigned to Pfizer, Inc. 

© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search